Fierce Healthcare

SEPTEMBER 11, 2023

billion union with Optum, even as the feds take a closer look at the deal. billion union with Optum, even as the feds take a closer look at the deal. Shareholders in home health company Amedisys have approved its $3.3 Shareholders in home health company Amedisys have approved its $3.3

126

126

STAT

MARCH 14, 2024

LONDON —   AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.   AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

111

111

STAT

APRIL 11, 2024

We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. Is biotech stale? And remember Dendreon? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Read the rest…

96

96

Pharmaceutical Technology

MARCH 19, 2024

In addition to drug discovery deals, NVIDIA also announced partnerships with J&J MedTech and GE Healthcare for genAI in MedTech.

112

112

STAT

MARCH 26, 2024

Troubled hospital operator Steward Health Care, grappling with a financial crisis that’s engulfed its eight Massachusetts hospitals, has moved to shore up its finances by striking a deal to sell its nationwide physician network to insurance giant UnitedHealth’s Optum Care unit.

Hospitals 132

Hospitals Documentation Insurance 132

Fierce Pharma

APRIL 25, 2024

CEO Pascal Soriot argued the deals were made to build the company’s future. . | After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.

Vaccines 87

Vaccines 87

pharmaphorum

MARCH 11, 2024

Boehringer Ingelheim has taken an option on a family of GPR52 agonist compounds with potential in schizophrenia from Sosei Heptares, in a €755m deal

Compounding 92

Compounding 92

Fierce Pharma

APRIL 4, 2024

As Teva advances its Pivot to Growth strategy under CEO Richard Francis, the company is making good on its pledge to beef up its biosimilar pipeline through outside deals. Teva has unveiled a fresh in-licensing accord with Spain’s mAbxience to chip in on an investigational biosimilar spanning multiple oncology indications.

86

86

pharmaphorum

NOVEMBER 30, 2023

billion deal to buy ImmunoGen and its marketed ovarian cancer drug. AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1

110

110

pharmaphorum

MARCH 19, 2024

AstraZeneca upgrades its radiopharma alliance with Fusion Pharma, opting to buy the biotech outright in a deal worth around $2 billion

95

95

Fierce Healthcare

NOVEMBER 17, 2023

The Federal Trade Commission (FTC) has stepped in to block a California hospital deal it said will result in less competition and higher healthcare costs. |

Hospitals 122

Hospitals 122

Fierce Healthcare

FEBRUARY 27, 2024

LOS ANGELES — Healthcare data and tech company Veradigm is picking up ScienceIO in a $140 million deal to build out large language models for healthcare. | Veradigm plans to use the company's platform to create its own proprietary large language models on its own massive dataset, which includes 400,000 providers and over 200 million patients. (..)

130

130

Fierce Pharma

FEBRUARY 28, 2024

On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business development grabs—especially on the comme | On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business (..)

86

86

European Pharmaceutical Review

APRIL 23, 2024

The deal is valued at up to $380 million in upfront and milestone payments. ” AstraZeneca to boost cell therapy operations with $300m manufacturing investment The post BMS inks CAR T cell therapy manufacturing deal with Cellares appeared first on European Pharmaceutical Review.

73

73

STAT

OCTOBER 11, 2023

New data from Pitchbook and the National Venture Capital Association show that both the number of deals and the amount of money that’s being invested in life science companies are down significantly. So far this year, there have been 1,384 VC deals struck in the field, the lowest figure since 2013.

124

124

Fierce Pharma

DECEMBER 14, 2023

Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019.

143

143

pharmaphorum

DECEMBER 4, 2023

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that if consummated will thrust it into the increasingly competitive market for incretin-based therapies for diabetes and obesity. The Swiss pharma group has agreed to pay $2.7

108

108

European Pharmaceutical Review

MARCH 11, 2024

The manufacturer Olympus Corporation has announced the rescission of an earlier acquisition deal due to reported data integrity issues of medical device products from Taewoong Medical Co., Data integrity issues The concerns around these products were found after the closing of the deal, Olympus noted.

80

80

pharmaphorum

JANUARY 1, 2024

Roche has agreed a $295 million deal to buy a point-of-care diagnostics platform from LumiraDx, which recently went into administration

93

93

Fierce Healthcare

SEPTEMBER 26, 2023

Virgin Pulse and benefits administrator HealthComp are set to merge in a $3 billion deal that aims to drive lower costs and improve outcomes for employers. Virgin Pulse and benefits administrator HealthComp are set to merge in a $3 billion deal that aims to drive lower costs and improve outcomes for employers.

125

125

STAT

FEBRUARY 5, 2024

billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.     Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.

Pharmaceutical Companies 138

Pharmaceutical Companies Pharmaceutical Companies 138

pharmaphorum

NOVEMBER 23, 2023

AstraZeneca joins KRAS push in cancer with Chinese deal Phil.Taylor Thu, 23/11/2023 - 16:46 Bookmark this

128

128

pharmaphorum

FEBRUARY 27, 2024

Novo Nordisk has signed a wide-ranging deal with US molecular glue biotech Neomorph that could be worth up to $1.46

96

96

Fierce Pharma

NOVEMBER 20, 2023

s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. s drug pricing policy, the pharma industry has secured an improved government spending deal. After blasting the U.K.’s After blasting the U.K.’s

109

109

pharmaphorum

JANUARY 2, 2024

Astellas has licensed up to four macrophage enhancer drugs with potential as cancer immunotherapies from Elpiscience in a $1.7bn deal

98

98

European Pharmaceutical Review

DECEMBER 22, 2023

Under the terms of the deal, BMS will acquire all outstanding shares of Karuna Therapeutics common stock for $330.00 The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for a total of $14.0

FDA 93

FDA 93

Fierce Healthcare

MARCH 27, 2024

Steward Health Care is planning to sell off its physician group to UnitedHealth Group’s Optum in order to right its struggling finances, according to documents filed with Massachusetts state regula | The proposed deal is under review from Massachusetts' healthcare regulator, but has already drawn antitrust concerns from federal lawmakers who pointed (..)

Documentation 92

Documentation 92

Fierce Healthcare

JUNE 26, 2023

Amedisys on Monday agreed to be acquired by UnitedHealth's Optum unit in an all-cash deal while also scraping a previous all-stock deal offer from previous suitor Option Care Health. UnitedHealth Group has once again flexed its muscles and outbid a competitor to pick up another home health asset.

114

114

Fierce Healthcare

FEBRUARY 13, 2024

Private equity firms have seen plenty of potential in the rapidly growing Medicare Advantage space, but deal volumes are slowing, according to a new report. Private equity firms have seen plenty of potential in the rapidly growing Medicare Advantage space, but deal volumes are slowing, according to a new report.

103

103

Fierce Healthcare

APRIL 8, 2024

billion across 133 deals, with an average deal size of $20.6 Digital health startups are navigating a tougher funding environment with lower check sizes and more attention to evidence-based outcomes in 2024. | In the first quarter, U.S. digital health startups raised $2.7 million, according to an analysis by Rock Health.

78

78

Drug Store News

SEPTEMBER 1, 2023

Four weeks of anniversary deals start Sept. 1 and run through Sept. 28, with new products and promotions each week, both in-store and online.

105

105

pharmaphorum

FEBRUARY 5, 2024

The deal includes $11 billion upfront to buy the fill-finish sites that Novo Nordisk said will enable “an expansion of the manufacturing capacity at scale and speed while providing future optionality and flexibility for Novo Nordisk’s existing supply network.”

89

89

Fierce Pharma

FEBRUARY 1, 2024

Even after the acquisitions of Prometheus and Acceleron, Merck is ready to make more deals in the $1 to $15 billion range, according to CEO Rob Davis.

116

116

Fierce Healthcare

JANUARY 25, 2024

Regulators are pumping the brakes on Novant Health’s deal to buy two North Carolina hospitals from Community Health Systems (CHS), citing concerns of higher healthcare costs and little incentive fo | The transaction for Lake Norman Regional Medical Center, Davis Regional Medical Center and other assets would give Novant Health 65% control of the inpatient (..)

Hospitals 104

Hospitals 104

Fierce Healthcare

NOVEMBER 7, 2022

Walgreens' VillageMD inks $9B deal to buy Summit Health, marking largest physician deal of the year. Mon, 11/07/2022 - 11:57.

120

120

STAT

NOVEMBER 20, 2023

and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. LONDON — The U.K.

106

106

Fierce Pharma

JANUARY 9, 2024

San Francisco—Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates | Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates, Pfizer’s newly minted chief oncology officer Chris Boshoff, Ph.D.,

85

85